Peregrine Ophthalmic
Singapore, Singapore· Est.
Singapore‑based biotech delivering liposomal sustained‑release eye drugs, starting with Lipolat for glaucoma.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Singapore‑based biotech delivering liposomal sustained‑release eye drugs, starting with Lipolat for glaucoma.
OphthalmologyGlaucomaCosmetic Ophthalmology
Technology Platform
Liposomal nanocarrier system for sustained release of ophthalmic drugs, enabling months‑long therapeutic exposure from a single administration.
Opportunities
Sustained‑release glaucoma therapy can improve adherence and capture a large share of the global glaucoma market; the cosmetic orbital‑fat indication opens a high‑margin aesthetic segment.
Risk Factors
Regulatory approval timelines, scale‑up manufacturing challenges, and competition from existing prostaglandin analogues and other sustained‑release ocular devices could limit market penetration.
Competitive Landscape
Competitors include traditional prostaglandin drops (e.g., Bimatoprost) and sustained‑release platforms like Allergan’s Bimatoprost SR; Peregrine differentiates via a fully injectable liposomal formulation offering months‑long dosing.